<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>esophageal cancer on Personal website of Di Shao</title>
    <link>https://dishao.netlify.app/tags/esophageal-cancer/</link>
    <description>Recent content in esophageal cancer on Personal website of Di Shao</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en</language><atom:link href="https://dishao.netlify.app/tags/esophageal-cancer/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019) A multicenter, phase 2 study</title>
      <link>https://dishao.netlify.app/project/nic_escc2019/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://dishao.netlify.app/project/nic_escc2019/</guid>
      <description>BACKGROUND Optimal treatment for resectable esophageal squamous cell carcinoma (ESCC) is controversial, especially in the context of potential benefit of combining PD-1 blockade with neoadjuvant therapy.
METHODS This phase 2 study aimed to assess neoadjuvant camrelizumab plus chemotherapy in this population. Patients (clinical stage II-IVA) received two cycles of neoadjuvant chemoimmunotherapy (NIC) with camrelizumab (200 mg on day 1) plus nab-paclitaxel (260 mg/m2 in total on day 1 and day 8) and cisplatin (75 mg/m2 in total on days 1-3) of each 21-day cycle.</description>
    </item>
    
  </channel>
</rss>
